Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses
- 25 September 2019
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 59 (3) , 371-382
Abstract
Amisulpride is an antipsychotic used in a wide range of doses. One of the major adverse events of amisulpride is hyperprolactinemia, and the drug might also induce body weight gain.Keywords
Funding Information
- Swiss National Research Foundation (320030-120686)
This publication has 33 references indexed in Scilit:
- Estimating Dopamine D2 Receptor Occupancy for Doses of 8 AntipsychoticsJournal of Clinical Psychopharmacology, 2013
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Safety and tolerability of antipsychotics: focus on amisulprideDrug, Healthcare and Patient Safety, 2010
- Hyperprolactinemia with Antipsychotic Drugs in Children and AdolescentsInternational Journal of Pediatric Endocrinology, 2010
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Current guidelines and their recommendations for prolactin monitoring in psychosisJournal of Psychopharmacology, 2008
- Therapeutic drug monitoring for optimizing amisulpride therapy in patients with SchizophreniaJournal of Psychiatric Research, 2007
- Quantification of Lean BodyweightClinical Pharmacokinetics, 2005
- Antipsychotic-Induced HyperprolactinaemiaDrugs, 2004
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976